ImmunityBio, Inc. IBRX Total Operating Expenses
Discontinued — last reported Q4 '24
Total Operating Expenses at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: ImmunityBio, Inc.’s 10-K, filed March 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total operating expenses?
- ImmunityBio, Inc. (IBRX) reported total operating expenses of $76.95M in Q4 2024.
- How has ImmunityBio, Inc.'s total operating expenses changed year-over-year?
- ImmunityBio, Inc.'s total operating expenses decreased by 10.0% year-over-year, from $85.53M to $76.95M.
- What is the long-term trend for ImmunityBio, Inc.'s total operating expenses?
- Over 3 years (2021 to 2024), ImmunityBio, Inc.'s total operating expenses has grown at a 2.7% compound annual growth rate (CAGR), from $331.21M to $358.93M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.